LO2A Drops Lessen Dry Eye Symptoms, Even Outperform Systane on Some Measures

Wize Pharma‘s LO2A eye drops result in clinically meaningful improvements in dry eye signs and symptoms in people with Sjögren’s syndrome, topline results from an exploratory Phase 4 trial show. The treatment continued to demonstrate a good safety profile, and was found to be at least as…

Wize Pharma Gets Green Light to Start Phase 4 Trial of Eye Drops in Sjogren’s Patients

The protocol of a Phase 4 trial testing Wize Pharma‘s LO2A eye drops for the treatment of dry eye symptoms in Sjogren’s syndrome patients has received regulatory approval. Clearance from the Institutional Review Board (IRB) means the study is now allowed to start. The double-blind trial (NCT03319420), to be…